Literature DB >> 7994265

Bone marrow transplantation for primary refractory acute leukaemia.

J Mehta1, R Powles, C Horton, S Milan, J Treleaven, D Tait, D Catovsky.   

Abstract

Twenty-four patients with primary resistant acute leukaemia received bone marrow transplants (BMTs) from matched sibling, syngeneic, matched unrelated, or mismatched family donors as treatment for induction failure. Three (12.5%) patients are alive and well 2-10 years after transplantation. Four (16.7%) patients died of transplant-related complications early post-transplant and remission status could not be determined. Two patients did not achieve complete remission (CR) and died of cytomegalovirus pneumonitis 3 months post-transplant. One patient died of graft failure. CR was obtained in 17 of 20 (85%) evaluable patients after BMT. Ten of 17 (58.8%) patients achieving CR died of transplant-related complications 1-10 months post-transplant. Four of 17 (23.5%) patients who had achieved CR relapsed after transplant. We conclude that a high proportion of patients failing to achieve remission with aggressive conventional chemotherapy achieve CR with BMT and a small proportion become long-term survivors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994265

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Authors:  Paul Ferguson; Robert K Hills; Angela Grech; Sophie Betteridge; Lars Kjeldsen; Michael Dennis; Paresh Vyas; Anthony H Goldstone; Donald Milligan; Richard E Clark; Nigel H Russell; Charles Craddock
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

2.  Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Authors:  Daniel J Weisdorf; Heather R Millard; Mary M Horowitz; Parvinder S Hyare; Richard Champlin; Vincent Ho; Marco Mielcarek; Andrew Rezvani; Keith Stockerl-Goldstein; Hanna J Khoury; Marcos De Lima; Wael Saber; Brenda Sandmaier; Mei Jie Zhang; Mary Eapen
Journal:  Cancer       Date:  2017-01-24       Impact factor: 6.860

3.  Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Authors:  Kumudha Balakrishnan; Farhad Ravandi; Shanta Bantia; Anna Franklin; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-15

4.  Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.

Authors:  H T Greinix; F Keil; S A Brugger; E Reiter; W Linkesch; K Lechner; B Schneider; K U Dieckmann; G Fischer; I Schwarzinger; O Haas; W Hinterberger; C Mannhalter; K Geissler; P Hocker; U Jager; P Kalhs
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

5.  Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.

Authors:  Elias Jabbour; Naval Daver; Richard Champlin; Michael Mathisen; Betul Oran; Stefan Ciurea; Issa Khouri; A Megan Cornelison; Hady Ghanem; Marylou Cardenas-Turanzas; Uday Popat; Farhad Ravandi; Sergio Giralt; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian; Marcos de Lima
Journal:  Am J Hematol       Date:  2014-03-07       Impact factor: 10.047

6.  Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.

Authors:  Wei Tang; Xing Fan; Ling Wang; Jiong Hu
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.